Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Inhalation Sciences Sweden Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Inhalation Sciences Sweden şirketinin toplam hissedar öz sermayesi SEK13.0M ve toplam borcu SEK1.1M olup, bu da borç-öz sermaye oranını 8.4% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK18.2M ve SEK5.2M dir.

Anahtar bilgiler

8.4%

Borç/özkaynak oranı

SEK 1.09m

Borç

Faiz karşılama oranı	n/a
Nakit	SEK 7.83m
Eşitlik	SEK 12.95m
Toplam yükümlülükler	SEK 5.21m
Toplam varlıklar	SEK 18.17m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

We're Not Counting On Inhalation Sciences Sweden (NGM:ISAB) To Sustain Its Statutory Profitability

Dec 29

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ISAB 'nin kısa vadeli varlıkları ( SEK15.8M ) kısa vadeli yükümlülüklerini ( SEK4.8M ) aşıyor.

Uzun Vadeli Yükümlülükler: ISAB şirketinin kısa vadeli varlıkları ( SEK15.8M ) uzun vadeli yükümlülüklerini ( SEK442.0K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ISAB şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: ISAB 'nin borç/öz sermaye oranı son 5 yılda 55.2% seviyesinden 8.4% seviyesine düştü.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ISAB şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: ISAB serbest nakit akışı her yıl % 1.5 1.3 yıl yetecek nakit akışına sahip olacaktır.

Inhalation Sciences Sweden Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Inhalation Sciences Sweden AB (publ) to Report Q2, 2024 Results on Aug 28, 2024

Inhalation Sciences Sweden AB (publ) to Report Q1, 2024 Results on May 28, 2024

Inhalation Sciences Sweden AB (publ), Annual General Meeting, May 14, 2024

Inhalation Sciences Sweden AB (publ) to Report Fiscal Year 2023 Results on Feb 28, 2024

Third quarter 2023 earnings released: kr0.098 loss per share (vs kr0.31 loss in 3Q 2022)

New major risk - Share price stability

Inhalation Sciences Sweden AB (publ) to Report Q3, 2023 Results on Nov 22, 2023

New major risk - Revenue and earnings growth

Inhalation Sciences Sweden AB (publ) to Report Q2, 2023 Results on Aug 29, 2023

New minor risk - Shareholder dilution

First quarter 2023 earnings released: kr0.20 loss per share (vs kr0.30 loss in 1Q 2022)

Inhalation Sciences Receives Formal Clearance to Begin the Trial of Inhalation Study

Inhalation Sciences Sweden AB (publ) to Report Fiscal Year 2022 Results on Feb 28, 2023

Third quarter 2022 earnings released: kr0.31 loss per share (vs kr0.40 loss in 3Q 2021)

No independent directors

Second quarter 2022 earnings released: kr0.36 loss per share (vs kr0.56 loss in 2Q 2021)

Inhalation Sciences Sweden AB (publ) Announces Resignation of Klaus Gottwald from Its Board of Directors

Inhalation Sciences Receives Landmark FDA Approval for Co-Financing of its Study to Validate Dissolvit as a Standard Research Method in the US

First quarter 2022 earnings: EPS and revenues miss analyst expectations

No independent directors

Full year 2021 earnings: EPS and revenues miss analyst expectations

Inhalation Sciences Sweden AB (publ), Annual General Meeting, May 06, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Inhalation Sciences Submits Whitepaper to FDA Aiming to Establish DissolvIt® as an FDA-Recommended Standard Research Method in US

Inhalation Sciences Announces Positive Study Results

Second quarter 2021 earnings released: kr0.56 loss per share (vs kr1.92 profit in 2Q 2020)

Investor sentiment improved over the past week

Inhalation Sciences Completes Enrolment in PreciseInhale Clinical Trial

Inhalation Sciences Sweden AB (Publ) Receives CTA Approval for Landmark Clinical Trial of Preciseinhale

Investor sentiment improved over the past week

First quarter 2021 earnings released: kr0.40 loss per share (vs kr0.068 profit in 1Q 2020)

Inhalation Sciences AB Provides Revenue Guidance for the Full Year of Fiscal 2021

New 90-day low: kr10.30

We're Not Counting On Inhalation Sciences Sweden (NGM:ISAB) To Sustain Its Statutory Profitability

Inhalation Sciences Appoints Paolo Raffaelli as New Chief Commercial Officer to Drive Global Sales

Market bids up stock over the past week

Inhalation Sciences Receives New Order Worth EUR 196,000 from University of Vienna

New 90-day low: kr10.80

Inhalation Sciences Announces to Successfully Installed its First Ever Commercial Version of the in Vitro Dissolvit Module at the Swiss Laboratory of a Long-Term ISAB Customer

An undisclosed buyer acquired an unknown stake in Ziccum AB (publ) (NGM:ZICC) from Inhalation Sciences Sweden AB (publ) (NGM:ISAB) for approximately SEK 21.2 million.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin